Asthma Trial Design To Be Focus Of Advisory Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
GSK's investigational LABA could be the most impacted product as FDA's Pulmonary-Allergy Drugs Advisory Committee considers how to evaluate outcomes in the class.
You may also be interested in...
FDA Calls For Class-Wide REMS For LABA Asthma Drugs
On top of a class-wide Risk Evaluation and Mitigation Strategy for the long acting beta-2 adrenergic agonist class of asthma drugs, FDA is going to work through its Safe Use partners to monitor whether actual use adjusts based on the new safety measures
FDA Calls For Class-Wide REMS For LABA Asthma Drugs
On top of a class-wide Risk Evaluation and Mitigation Strategy for the long acting beta-2 adrenergic agonist class of asthma drugs, FDA is going to work through its Safe Use partners to monitor whether actual use adjusts based on the new safety measures
FDA Calls For Class-Wide REMS For LABA Asthma Drugs
LABA asthma drugs are the latest group of medications to be hit with a class-wide Risk Evaluation and Mitigation Strategies requirement.